Latest news and updates from Sathgen Therapeutics

December 2023

SiliconIndia magazine recognized us as the one of the ‘10 Most Promising Drug Discovery & Development Companies – 2023‘.
Read more about how we are “Fusing Nature & Science for Breakthrough Anti-Cancer Solutions” at link.

October 2023

We have presented our latest work on clinical development of our anti-cancer and anti-viral molecules at the Pharma Partnering Summit on October 19-20, 2023 at Boston, MA.

August 2023

We completed the dosing of the first two cohorts of healthy volunteers with our lead anti-cancer and anti-viral drug, MSP008-22, in a phase 1 clinical trial. No serious adverse events were reported. The milestone was covered by various news outlets in India, USA, UK, Germany, Spain, France.

July 2023

We completed the dosing of the first patient cohort with our lead anti-cancer drug, MSP008-22, a phase 1 clinical trial carried out in patients with advanced solid tumors. This milestone was covered as press releases in India, USA, UK, Germany, Spain, France.

May 2023

We showcased our work on the anti-cancer drugs at the Pharma Partnering Summit in San Diego, CA, USA, a conference that brings together the pharmaceutical and biotech worlds.

April 2023

The healthy volunteer trial entitled “A Phase I, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose and Multiple Ascending Dose Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of MSP008-22 in Healthy Adult Volunteers” was initiated in April 2023.

January 2023

Our first-in-human patient trial entitled “A Single Ascending Dose, Phase I Trial to Assess the Safety, Tolerability and Pharmacokinetic Profile of MSP008-22 in Patients with Advanced Solid Tumors” was initiated in January 2023.

December 2017

Patent for MSP008-22 anti-cancer compound granted in USA and Japan.

June 2011

Patent for Synthesis of Cleistanthin A and its derivatives thereof granted in India, USA, Germany, Netherlands, France,
UK, Mexico, South Africa, Australia, New Zealand, Israel, Japan, and Canada.

February 2009

Patent for Process for Synthesis of Cleistanthin granted in India, Australia, New Zealand, Mexico, Canada, UK, France, Netherlands, Germany, and South Africa.

Scroll to top